1MED is a Contract Research Organisation providing regulatory strategy, clinical trial management and quality assurance services to the medical device and pharmaceutical industry.
As a successful and well-regarded CRO, 1MED supports the commercialisation of new innovative products and technologies improving patients’ access to new solutions. It is recognised as a high quality and reliable outsourced provider to obtain product certification on time and budget with a 100% product approval rate to date.
Apposite recognises that there will be an increased need to work with specialists such as 1MED due to the increasing complexity and regulatory requirements of medical devices due to recent MDR and IVDR frameworks. The company has a strong growth track record benefiting from a loyal and recurrent client base. Apposite investment will enable it to capitalise further on outstanding growth opportunities in the global CRO market, strengthening and widening the company’s service offering and further expanding its geographic coverage.